Home › Non-Small Cell Lung Cancer › Nevada
Non-Small Cell Lung Cancer clinical trials in Nevada
25 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Nevada.
Cities in Nevada
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04267848A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Renown Health Medical Oncology, Reno
- Renown Office of Clinical Research, Reno
- Renown Regional Medical Center, Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07144280A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207), Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07513376A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06868277A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0037), Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312137Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134), Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06170788Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Las Vegas
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06357533A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Renown Regional Medical Center, Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06561386Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Renown Regional Medical Center, Reno
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07100080A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Renown Regional Medical Center /ID# 273535, Reno
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06568939Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Cancer Care Specialists, Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07195695Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- OptumCare Nevada, Las Vegas
- Local Institution - 007-938A, Las Vegas
- Local Institution - 007-938B, Las Vegas
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT04613596Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Renown Regional Medical Center, Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06899126A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Cancer Care Specialists, Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07541170A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Cancer Care Specialists, Reno
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Comprehensive Cancer Centers of Nevada, Las Vegas
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Research Site, Las Vegas
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06350097Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #55, Las Vegas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT05176483A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
RecruitingPhase 2
18 Minutes · All sexes · Updated May 5, 2026 · NCT06031688Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- OptumCare Cancer Care at Seven Hills, Henderson
- OptumCare Cancer Care at Charleston, Las Vegas
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 17, 2026 · NCT06418204GEMINI-NSCLC: NSCLC Biomarker Study
- OptumCare Cancer Care, Las Vegas
- Hope Cancer Care of Nevada, Las Vegas
- Cancer Care Specialists Reno, Reno
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 5, 2026 · NCT05236114A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 110, Las Vegas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 21, 2025 · NCT05914116From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.